A majority of m6A residues are in the last exons, allowing the potential for 3′ UTR regulation

By Shengdong Ke, E. A. Alemu, C. Mertens, Emily C. Gantman, J. Fak, Aldo Mele, B. Haripal, Ilana Zucker-Scharff, M. J. Moore, Christopher Y. Park and 5 more. Genes & Development, 2015

763 citations recorded by the source corpus.

Ke et al. found that >70% of m6A residues are present in the 3′-most (last) exons, with a sharp rise within 150–400 nucleotides of the start of the last exon. This report also suggests a role of m6A modification in regulating proximal alternative polyA choice.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/08a02ccaca46b9d53f5e589db82fec0099cb4780

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Kate D. Meyer
2. Samie R. Jaffrey
3. Qinghua Cui
4. Yuan Zhou
5. Pan Zeng
6. Yan-Hui Li
7. Ziding Zhang
8. Quan Zou

Citations in the corpus

• Rethinking m6A Readers, Writers, and Erasers (2017, background): “More recent m6A mapping studies have further refined the localization of m6A to enrichment in the 5´ end of the terminal exon, which often includes the stop codon (Batista et al. 2014, Ke et al. 2015).”
• SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features (2016, methodology): “Because the m6A sites are not randomly distributed along the transcripts (3,4,22), to avoid prominent bias, we assigned 10-fold likelihood to be chosen as the negative sample to a non-m6A site near a known m6A site, enabling position-corrected sets of negative samples.”
• m6A RNA methylation: from mechanisms to therapeutic potential (2021, neutral): “…of RNA occurs in most eukaryotes and is the most prevalent internal mRNA modification in mammals, where it is present at tens of thousands of sites across the transcriptome, at a frequency of 0.15 – 0.6% of all adenosines (Table 1) (Dominissini et al , 2012; Liu et al , 2014; Ke et al , 2015).”
• Gene2vec: gene subsequence embedding for prediction of mammalian N6-methyladenosine sites from mRNA (2018, methodology): “Recently, Zhou et al. established an m 6 A data set from published single-nucleotide-resolution maps of human and mouse m 6 A sites (Ke et al. 2015; Linder et al. 2015).”
• METTL3 promotes translation in human cancer cells (2016, methodology): “Our m(6)A profiles correlate well between replicates and with a published dataset (Figures S1A and S1B) (Ke et al., 2015).”